Envisia Therapeutics, Inc. — Form D
Envisia Therapeutics, Inc. of MORRISVILLE, NC, a company, filed a Form D exempt-offering notice with the SEC on 2016-03-17. The offering totals $16.5M, of which $10.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2016-03-17
- Form: D
- Accession: 0001655970-16-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $16.5M
- Amount sold: $10.1M
- Remaining: $6.4M
- Investors: 9
- Date of first sale: 2016-03-11
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-259444
Issuer
- Name: Envisia Therapeutics, Inc.
- CIK: 0001655970
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2013
- Address: 419 DAVIS DRIVE, MORRISVILLE, NC, 27560
- Phone: 919.973.1440
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Stephen Bloch | Director | Parsippany, NJ |
| Neal Fowler | Director | DURHAM, NC |
| Adrienne Graves | Director | Dedham, MA |
| Ed Mathers | Director | TIMONIUM, MD |
| Gary Phillips | Director | Newton, MA |
| William Yelle | Director | MORRISVILLE, NC |
| Eric Linsley | Executive Officer | Durham, NC |
| Ben Yerxa | Executive Officer | MORRISVILLE, NC |
| Seth Rudnick | Director | DURHAM, NC |
Other filings by this issuer (1)
More